Analysts' Top Healthcare Picks: Encompass Health (EHC), Castle Biosciences (CSTL)
Castle Biosciences (CSTL) Receives a Buy From Scotiabank
Castle Biosciences Price Target Maintained With a $37.00/Share by Stephens & Co.
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $34
Baird Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $37
Castle Biosciences Analyst Ratings
Baird Maintains Outperform on Castle Biosciences, Raises Price Target to $37
Castle Biosciences Analyst Ratings
Baird Maintains Outperform on Castle Biosciences, Maintains $34 Price Target
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cross Country Healthcare (CCRN), Castle Biosciences (CSTL) and Andlauer Healthcare Group (OtherANDHF)
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Castle Biosciences (CSTL)
Castle Biosciences Analyst Ratings
Scotiabank Maintains Sector Outperform on Castle Biosciences, Raises Price Target to $37
Castle Biosciences Analyst Ratings
Outperform Rating for Castle Biosciences Amid Strong Market Presence and Growth Prospects
Analysts Conflicted on These Healthcare Names: Castle Biosciences (CSTL), DENTSPLY SIRONA (XRAY) and Silk Road Medical (SILK)
Analysts Conflicted on These Healthcare Names: Immunocore Holdings (IMCR), Voyager Therapeutics (VYGR) and Castle Biosciences (CSTL)
Buy Rating Affirmed for Castle Biosciences on Strong Performance and Positive Outlook
Scotiabank Reaffirms Their Buy Rating on Castle Biosciences (CSTL)
Guggenheim Initiates Coverage On Castle Biosciences With Buy Rating, Announces Price Target of $25